Unlocking Q3 Potential of Clorox (CLX): Exploring Wall Street Estimates for Key Metrics

Wall Street analysts expect Clorox (CLX) to post quarterly earnings of $1.57 per share in its upcoming report, which indicates a year-over-year decline of 8.2%. Revenues are expected to be $1.71 billion, down 5.5% from the year-ago quarter.The consensus EPS estimate for the quarter has been revised 2.2% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.That said, let's delve into the average estimates of some Clorox metrics that Wall Street analysts commonly model and monitor.Analysts forecast 'Net Revenue- Health and Wellness' to reach $597.23 million. The estimate indicates a change of -1.9% from the prior-year quarter.Based on the collective assessment of analysts, 'Net Revenue- Household' should arrive at $515.48 million. The estimate indicates a change of -2% from the prior-year quarter.Analysts' assessment points toward 'Net Revenue- International' reaching $258.40 million. The estimate indicates a year-over-year change of -16.7%.The combined assessment of analysts suggests that 'Net Revenue- Lifestyle' will likely reach $314.14 million. The estimate indicates a change of -0.3% from the prior-year quarter.It is projected by analysts that the 'Organic Revenue Growth - International' will reach 6.0%. Compared to the current estimate, the company reported 48% in the same quarter of the previous year.The consensus estimate for 'Income before income taxes- Health and Wellness' stands at $176.17 million. The estimate compares to the year-ago value of $154 million.The collective assessment of analysts points to an estimated 'Income before income taxes- International' of $27.86 million. The estimate compares to the year-ago value of $38 million.According to the collective judgment of analysts, 'Income before income taxes- Lifestyle' should come in at $68.36 million. Compared to the current estimate, the company reported $64 million in the same quarter of the previous year.The consensus among analysts is that 'Income before income taxes- Household' will reach $73.02 million. Compared to the present estimate, the company reported $74 million in the same quarter last year.View all Key Company Metrics for Clorox here>>>Shares of Clorox have demonstrated returns of -3.6% over the past month compared to the Zacks S&P 500 composite's -0.7% change. With a Zacks Rank #3 (Hold), CLX is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Clorox Company (CLX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks